SUPN News and Press, Supernus Pharmaceuticals Inc. From 05/13/21

We did a comparison of 3 small-cap biotech stocks (SUPN, ENTA & EGRX) which were ranked highly in our quantitative model. SUPN demonstrated outperformance in growth and profitability metrics. Both SUPN and EGRX are led by Founder-CEO. Overall, we believe SUPN could be a lo...

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2021 Earnings Conference Call May 05, 2021, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Jack Khattar - Founder, President, CEO, Secretary & Director James Kelly - EVP & CFO Conference Call Participants Kenneth Cacciatore - Co...

Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q1 2021 Earnings Call May 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call Trans...

Supernus Pharmaceuticals (SUPN): Q1 GAAP EPS of $0.11 misses by $0.11.Revenue of $130.9M (+37.8% Y/Y) beats by $3.71M.Full Year 2021 Financial Guidance: Total revenues of $550M - $580M vs. consensus of $569.47M; Operating earnings of $65M - $90M and Effective Tax Rate of 28% - 31%.Press ...

First quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020 Qelbree™ approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021 Qelbree sNDA submission for adult ADHD anticipated in the third quarter of 2021 SPN-830 (apomorph...

ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Newron Pharmaceuticals S.p.A. (...

ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report bus...

Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded at a new 52-week high today of $32.01. This new high was reached on below average trading volume as 366,000 shares traded hands, while the average 30-day volume is approximately 699,000 shares. Based on a current price of $31.9...

After a ~1.2% loss yesterday despite the FDA approval for Qelbree in attention-deficit hyperactivity disorder (“ADHD”) in those aged 6 – 17 years, Supernus Pharmaceuticals ([[SUPN]] +9.0%) is trading sharply higher today.Based on two surveys conducted by the firm, Je...

iRhythm continues to trade lower as analysts evaluate the impact of Novitas rate update on the company. Meanwhile, the recent FDA approvals have led Truist Securities to upgrade Bristol Myers.iRhythm downgraded at BTIG on uncertain outlookThe revision of Novitas reimbursement rates ...